The effect of low molecular weight heparin (enoxaparin) on enhanced coagulation induced by crystalloid haemodilution.
The purpose of this study was to establish whether a low molecular weight heparin (enoxaparin) attenuated or abolished the enhanced coagulation induced by crystalloid fluid therapy. Twenty young, healthy male volunteers were injected subcutaneously with either enoxaparin 40 mg or saline on two separate occasions one week apart, in a randomised, blinded study. Twelve hours later, a blood sample was taken for thrombelastography analysis and haematocrit. Saline 14 ml.kg⁻¹ was then infused over thirty minutes and thrombelastography and haematocrit measurements repeated. There was a significant post-dilutional difference in the alpha angle (p = 0.002) and k-time (p = 0.001) between the two groups. There was a trend towards reduced shortening of r-time in the enoxaparin group compared to the saline control (p = 0.18). The findings suggest that enoxaparin diminished acceleration of clot formation due to haemodilution.
Llewellyn
R L
RL
Department of Anaesthesiology, University of Cape Town Medical School, South Africa. Richard.Llewellyn@uct.ac.za
James
M F M
MF
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D018592:Cross-Over Studies; D000077324:Crystalloid Solutions; D004311:Double-Blind Method; D017984:Enoxaparin / Q000494:pharmacology*; D006400:Hematocrit; D006438:Hemodilution / Q000379:methods*; D006801:Humans; D007552:Isotonic Solutions; D008297:Male; D012965:Sodium Chloride; D013916:Thrombelastography / Q000379:methods; D055815:Young Adult
D000925:Anticoagulants; D000077324:Crystalloid Solutions; D017984:Enoxaparin; D007552:Isotonic Solutions; D012965:Sodium Chloride